Evolocumab ameliorates myocardial fibrosis and improves metabolic syndrome–induced cardiac dysfunction in rats via inhibiting PCSK9/NLRP3 inflammasome and Caspase-1 / IL-1β pathways.

European Journal of Pharmacology | Issue in press | 2025

DOI: https://doi.org/10.1016/j.ejphar.2025.177499

Effect of Canagliflozin, an SGLT2 Inhibitor, in Comparison with Atorvastatin on Dexamethasone-Induced Hepatic Steatosis in Albino Rats

Current Drug Therapy | Vol. 15 | Issue 3 | 2020

DOI: https://doi.org/10.2174/1574885514666191007094424